Irbesartan slows progression of nephropathy in type 2 diabetes

Effect of irbesartan, amlodipine, and placebo on the course of patients with hypertension with nephropathy due to type 2 diabetes; the target blood pressure was similar in the 3 groups. Treatment with irbesartan was associated with a risk of the primary end point (doubling of the baseline serum creatinine, development of end-stage kidney disease, or death from any cause) that was 20% lower than placebo and 23% lower than amlodipine.